glp 1 and mash Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction–associated steatohepatitis (MASH): A real-world data analysis Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic

Increased Heart Rate at Rest: Fast or pounding heartbeat

Impact of brief exercise on circulating monocyte gene and microRNA expression: implications for atherosclerotic vascular disease

The GLP-1 pill is not only FDA-approved, but also the most affordable GLP-1 on the market today

The standalone BPC-157 protocol is a focused, lower-cost entry point for patients who want to explore peptide therapy for a specific concern, particularly gut health, mild joint issues, or general recovery support

Abstract AGC1 deficiency is a rare, early-onset encephalopathy caused by mutations in the SLC25A12 gene, encoding the mitochondrial aspartate/glutamate carrier isoform 1 (AGC1)

Personalized wellness consultations Calm, welcoming treatment environment Carefully structured IV protocols Optional IV membership programs for consistent care Frequently Asked Questions What is the clinical difference between an IV Push and an IV Infusion